Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.

Print this page

R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies

Primary Objective in the Dose Escalation Phase:
To evaluate safety and PK in order to determine an RP2D of REGN3767 as monotherapy and in combination with REGN2810 on patients with advanced malignancies, including lymphoma.

Primary Objective in the Dose Expansion Phase:
To assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by ORR.

Protocol Number: 051706
Phase: Phase I
Applicable Disease Sites: Melanoma, Skin
Other Skin
Drugs Involved: REGN3767
Principal Investigator: Roman Groisberg M.D.
Scope: National
Therapies Involved: Chemotherapy multiple agents systemic
Chemotherapy single agent systemic
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.